Trial reportJournal of the American College of Cardiology2023
Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction.
Trial report in Journal of the American College of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01920711 (A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction (PARAGON-HF)
Who cites it
31 citing papers in PubMed, 55 citations in OpenAlex.
- Multiparametric Assessment of Right Ventricular Dysfunction in Heart Failure: An Analysis From PARAGON-HF.Journal of the American Heart Association · 2025Trial
- Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial.Circulation. Heart failure · 2024Trial
- The predictive value of the TAPSE/PASP ratio for major adverse cardiovascular events in patients with chronic heart failure: evidence from a prolonged follow-up cohort.Annals of medicine · 2026Article
- A Congestive Hemodynamic Footprint Is Associated With Worse Clinical Outcomes in Lung Transplant Recipients.Pulmonary circulation · 2026Article
- Multi-Organ Crosstalk in HFpEF: Reframing a Cardiac Syndrome as a widespread Systemic Disease.Journal of precision medicine (Amsterdam, Netherlands) · 2026Article
- Prognostic Role of Immunonutritional Indices in Elderly Patients with HFpEF: Long-Term Follow-Up of the CONUT, PNI, and CALLy Scores.Journal of clinical medicine · 2026Article
- Echocardiographic Assessment of Right Ventricular-Pulmonary Arterial Coupling in Heart Failure: Prognostic Insights from a Systematic Review.Journal of clinical medicine · 2026Review
- Prevalence and Prognostic Value of Right Ventricular-Pulmonary Artery Uncoupling in Adults with Right-Sided Congenital Heart Disease.Journal of personalized medicine · 2026Article
- Assessment of Right Ventricular Function Prior to Transcatheter Tricuspid Valve Interventions.Current cardiology reports · 2026Review
- Right ventricular to pulmonary arterial uncoupling: clinical, functional and morphological insights in patients with hypertrophic cardiomyopathy.The international journal of cardiovascular imaging · 2026Article
- Association of the Severity of Pulmonary Valve Regurgitation on Biomarkers, Functional Capacity, and Complications in Patients with Heart Failure.Arquivos brasileiros de cardiologia · 2025Article
- Right ventricular-pulmonary arterial coupling and pulmonary hypertension in hemodialysis: insights into structural cardiac changes and clinical implications.Renal failure · 2025Article
- Oxylipins are Associated With Poor Right Ventricular to Pulmonary Artery Coupling and Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.The American journal of cardiology · 2025Article
- Improvement in Right Ventricular Function and Pulmonary Pressures in Patients With Severe Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction Treated With Sacubitril-Valsartan.Pulmonary circulation · 2025Article
- Carbohydrate antigen-125 (CA125): a marker of right ventricular dysfunction and poor prognosis in heart failure with preserved ejection fraction.International journal of cardiology. Heart & vasculature · 2025Article
- Clinical Usefulness of Right Ventricular-Pulmonary Artery Coupling in Patients with Heart Failure.Diagnostics (Basel, Switzerland) · 2025Review
- Advanced 4-chamber echocardiography techniques enable clinically matched precise characterization of heart disease progression in mice.Communications medicine · 2025Article
- Cardiac magnetic resonance markers of pre-clinical hypertrophic and dilated cardiomyopathy in genetic variant carriers.BMC medicine · 2025Article
- Early Echocardiographic Markers in Heart Failure with Preserved Ejection Fraction.Journal of cardiovascular development and disease · 2025Review
- Refining Prognostication and Therapeutic Guidance Through Advances in Right Heart Imaging Approaches.The Canadian journal of cardiology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
20 authors at 8 institutions in 10 countries.
Funding
Abstract
backgroundLimited data exist to characterize novel measures of right ventricular (RV) function and the coupling to pulmonary circulation in patients with heart failure and preserved left ventricular ejection fraction (HFpEF).
objectivesThis study sought to assess the clinical implications of RV function, the association with N-terminal pro-B-type natriuretic peptide, and the risk for adverse events among patients with HFpEF.
methodsThis study analyzed measures of RV function by assessing absolute RV free wall longitudinal strain (RVFWLS) and its ratio to estimated pulmonary artery systolic pressure (PASP) (RVFWLS/PASP ratio) in 528 patients (mean age 74 ± 8 years, 56% female) with adequate echocardiographic images quality enrolled in the PARAGON-HF trial. Associations with baseline N-terminal pro-B-type natriuretic peptide and with total HF hospitalizations and cardiovascular death were assessed, after accounting for confounders.
resultsOverall, 311 patients (58%) had evidence of RV dysfunction, defined as absolute RVFWLS <20%, and among the 388 patients (73%) with normal tricuspid annular planar systolic excursion and RV fractional area change, more than one-half showed impaired RV function. Lower values of RVFWLS and RVFWLS/PASP ratios were significantly associated with higher circulating N-terminal pro-B-type natriuretic peptide. With a median follow-up of 2.8 years, there were 277 total HF hospitalizations and cardiovascular deaths. Both absolute RVFWLS (HR: 1.39; 95% CI: 1.05-1.83; P = 0.018) and RVFWLS/PASP ratio (HR: 1.43; 95% CI: 1.13-1.80; P = 0.002) were significantly associated with the composite outcome. Treatment effect of sacubitril/valsartan was not modified by measures of RV function.
conclusionsWorsening RV function and its ratio to pulmonary pressure is common and significantly associated with an increased risk of HF hospitalizations and cardiovascular death in patients with HFpEF. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.